Latest Research And Development News

Fluence Corporation Limited reported a positive net operating cash flow of US$5.1 million for Q2 2025, boosting its cash reserves to US$12.7 million and maintaining solid liquidity through revolving credit and loan facilities.

Aruma Resources has confirmed maiden drilling plans at its Fiery Creek Copper Project in Queensland and secured $900,000 in a recent placement to accelerate exploration across its portfolio.

Strategic Elements Ltd has marked significant progress in its Energy Ink™ prototype trials and underground mining technology, maintaining a robust financial footing with $4.21 million cash and no debt.

PainChek Limited has secured a A$7.5 million placement to fuel its international expansion, with US FDA clearance for its adult pain assessment app expected imminently. The company reports strong license growth and a 26% revenue increase year-on-year.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir ahead of schedule, setting sights on expedited FDA approval leveraging the Animal Rule.

Knosys Limited sustains a robust $9.8 million Annual Recurring Revenue, extends its ANZ Bank contract, and accelerates AI-driven library technology development with promising early market feedback.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Dubber Corporation Limited has achieved underlying operating cashflow breakeven for the first time in its history in Q4 FY25, despite the looming impact of a major contract non-renewal. The company plans to offset margin losses through aggressive cost savings and revenue growth in FY26.

Zimi Limited has completed production of its Smoke Connect safety range, progressed Matter Connect certification, and moved Senoa manufacturing to a new facility, while engaging investors for a capital raise.

ReNerve Limited reported a robust 53% increase in annual revenue, driven by strategic partnerships and new regulatory approvals that broaden its global footprint in nerve repair.

BPH Global confirms that the seaweed Sesuvium portulacastrum accumulates valuable metals including gold and lithium, but shifts focus to biological extraction after chemical methods fall short.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.